Press release
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Size Projected To Reach 2.51 Billion By 2034 With A Cagr Of 6%
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors
What Is the Projected Growth of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The market for poly(ADP-ribose) polymerase (PARP) inhibitors has expanded quickly in the past few years. The size of this market is projected to increase from $6.53 billion in 2024 to $7.56 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. The historical growth of this market is linked to factors such as the rising prevalence of cancer, the growth of genetic testing, successful clinical trials, enhanced insurance coverage, and advancements in cancer research.
The market size of poly(ADP-ribose) polymerase (PARP) inhibitors is projected to expand rapidly in the approaching years, reaching a value of $13.45 billion by 2029, with a compound annual growth rate (CAGR) of 15.5%. This growth during the projected period can be linked to an increase in drug production and delivery, a surge in cases of BRCA-mutated cancers, a growing incidence of breast cancer, increased adoption of monoclonal antibodies, and heightened healthcare spending. Future trends within the projected period encompass improvements in biomarker research, the use of combined therapies, the incorporation of artificial intelligence into drug creation, advancements in therapy driven by biomarkers, and the creation of next-generation PARP inhibitors.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22102
What Are the Different Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segments?
The poly(ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented -
1) By Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Types
2) By Indication: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers, HRD-Positive Cancers, Maintenance Therapy
2) By Rucaparib: Ovarian Cancer, Prostate Cancer, Pancreatic Cancer
3) By Niraparib: First-Line Treatment, Recurrent Cancer Treatment, Late-Stage Cancer
4) By Talazoparib: Breast Cancer, Germline BRCA-Mutated Tumors, Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors, Investigational Therapies, Novel Combinations
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
What Are the Primary Drivers Shaping the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The poly(ADP-ribose) polymerase (PARP) inhibitors market is set to expand due to the increasing incidences of breast cancer. This ailment is characterized by uncontrolled growth of cells in the breast, which forms a malignant tumor with the potential to metastasize. Factors such as aging populations, lifestyle changes, genetic predisposition, hormonal imbalances, obesity, alcohol consumption, and increasing exposure to environmental risk factors are contributing to its rising prevalence. PARP inhibitors aid in breast cancer treatment by blocking the PARP enzyme from repairing DNA damage in the cancer cells, thereby causing the death of the cells, especially in tumors with BRCA1 or BRCA2 mutations. For instance, data from the National Breast Cancer Foundation, a US-based organization, stated in January 2025 that one out of every eight women in the United States will be diagnosed with breast cancer in their lifetimes. In 2024, the number of women diagnosed with invasive breast cancer was 310,720, and it was 2,800 for men. Consequently, the increasing prevalence of breast cancer is fuelling the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
Which Companies Are Leading in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
What Are the Major Trends Shaping the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Significant companies involved in the poly(ADP-ribose) polymerase (PARP) inhibitors sector are prioritizing the creation of progressive cancer therapies, such as medications specifically designed to address prevalent genetic alterations in some types of cancer. Anticancer medications, which serve to control the growth and spread of cancer cells or annihilate them, are being heavily researched. This category of drugs operates through a variety of processes, including disrupting cell division, inhibiting critical proteins that promote tumor growth, or boosting the patient's immune responses against cancer cells. For instance, Zydus Lifesciences Limited, a pharmaceutical company rooted in India, introduced IBYRA, an economically viable and tailored treatment alternative for HRD-positive and BRCA-positive cancer patients in India in March 2024. This generic version of the PARP inhibitor olaparib notably diminishes the treatment expenditure compared to its original counterpart.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/polyadp-ribose-polymerase-parp-inhibitors-global-market-report
What Are the Top Revenue-Generating Geographies in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
2. What is the CAGR expected in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
3. What Are the Key Innovations Transforming the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Industry?
4. Which Region Is Leading the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Size Projected To Reach 2.51 Billion By 2034 With A Cagr Of 6% here
News-ID: 4073440 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Poly
Poly(vinyl Acetate) Market Size Report 2025
On Mar 8, 2025, Global Info Research released a research report titled "Global Poly(vinyl Acetate) Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report provides detailed data analysis of the Poly(vinyl Acetate) market from 2020 to 2031. Including the market size and development trends of Poly(vinyl Acetate) Market, it analyzes market size indicators such as sales, sales volume, average price and CAGR, it also provides a…
Poly Aluminium Chloride Market Research Report 2023
Polyaluminium Chloride Market
Polyaluminium chloride (PAC) is manufactured in both liquid and powder form. The product is used in deodorants and antiperspirants, as a flocculant in water purification, in treatment of drinking / potable water, wastewater treatment and paper sizing.
In this report, poly alumnium chloride is classified into liquid and powder type. All the poly alumnium chloride products are converted into 30% Al2O3 content.
Due to the COVID-19 pandemic, the global…
Poly-Vents Market to Witness Remarkable Growth | Filtration Group Corporation; P …
Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Poly-Vents Market Analysis and Forecast, 2020 – 2027”. In this report, Researchers have analysed Strength, Weakness, opportunities and threats in the market and provides the unbiased picture of the market with the informative knowledge. The Poly-Vents Market report additionally states import/trade utilization, free market activity figures, cost, value, volume and gross edges.
The study bridges the historical…
Poly-Vents Market To Witness Astonishing Growth | Competitive Outlook By Filtrat …
The Latest survey report on Poly-Vents Market?research gives a holistic overview of the growth and other aspects of the industry in vital countries (regions). The regions provided in this market document show the geographical boundaries across the globe. This report is a wonderful guide to achieve an information or key data about market, emerging trends, product usage, customer inclinations, motivating factors for customers, competitor strategies, brand positioning, future trends, customer…
Poly Adenosine Diphosphate Ribose Polymerase Market Drivers
Poly adenosine diphosphate ribose polymerase (PARP) is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. These proteins aid in restoring the damage in DNA caused due to various factors such as exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors aid in blocking the enzyme important for the repair…
Poly Adenosine Diphosphate Ribose Polymerase Market Drivers
Poly adenosine diphosphate ribose polymerase (PARP) is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. These proteins aid in restoring the damage in DNA caused due to various factors such as exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors aid in blocking the enzyme important for the repair…
